(Q36788463)

16 August 2017

1 reference

title

Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor (English)

1 reference

16 August 2017

2

Susan E Bates

1 reference

16 August 2017

Elizabeth Fox

1

1 reference

16 August 2017

publication date

1 April 2007

1 reference

Expert Review of Anticancer Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

447-459

1 reference

Mechanisms of cancer drug resistance

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Drug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

The human ATP-binding cassette (ABC) transporter superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Expression of a multidrug-resistance gene in human tumors and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Expression of a drug resistance gene in human neuroblastoma cell lines: modulation by retinoic acid-induced differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Multiple drug resistance parameter expression in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Novel mechanisms of drug resistance in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Strategies for reversing drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Structure-activity relationships of a series of tariquidar analogs as multidrug resistance modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Pheophorbide a is a specific probe for ABCG2 function and inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Pharmacological strategies for overcoming multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

A Phase I study of infusional vinblastine in combination with the P-glycoprotein antagonist PSC 833 (valspodar).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Protein expression profiles indicative for drug resistance of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Gr

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Modulation of doxorubicin concentration by cyclosporin A in brain and testicular barrier tissues expressing P-glycoprotein in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Role of multidrug transporters in pharmacoresistance to antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

A comparison of extracellular levels of phenytoin in amygdala and hippocampus of kindled and non-kindled rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

The multidrug transporter hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of temporal lobe epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Increased drug delivery to the brain by P-glycoprotein inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.4.447

21 January 2018

Identifiers

DOI

10.1586/14737140.7.4.447

1 reference

16 August 2017

1 reference